Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Vikki Tang"'
Autor:
Vikki Tang, Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, Bryan Cho Wing Li, Ka Wing Ma, Wong Hoi She, Chung Mau Lo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Background Programmed cell death protein 1 (PD-1) pathway blockade with immune checkpoint inhibitors (ICIs) is a standard therapy in advanced hepatocellular carcinoma (HCC) nowadays. No strategies to overcome ICI resistance have been described. We ai
Externí odkaz:
https://doaj.org/article/5f87dbb432394523851e4b34b6953f4a
Autor:
Vikki Tang, Yu Cho Woo, David T W Lui, Alan Chun Hong Lee, Gerry Gin Wai Kwok, Tan To Cheung, R. Leung, Bryan Cho Wing Li, Karen S.L. Lam, Thomas Yau, Joanne Wing Yan Chiu, Chi Ho Lee, Carol H.Y. Fong
Publikováno v:
Endocrine Practice. 27:886-893
Objective Thyroid immune-related adverse events (irAEs) have been reported to have prognostic significance among patients with cancer treated with anti-programmed cell death-1 (PD1) and anti-programmed death-ligand 1 monotherapies. We evaluated the c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2e0da3c560fc929341a5f6e1ea1cbb1
https://doi.org/10.1016/j.eprac.2021.01.017
https://doi.org/10.1016/j.eprac.2021.01.017
Autor:
Thomas Yau, Vikki Tang, Wong Hoi She, Ka Wing Ma, Josephine Tsang, Gerry Gin Wai Kwok, Tan To Cheung, Albert C. Y. Chan, Bryan Cho Wing Li, Kit Shing, Joanne Chiu, Chung Mau Lo, Roland Leung
Publikováno v:
Advances in Therapy. 38:3900-3910
Treatment of hepatocellular carcinoma (HCC) recurrences following liver transplant (LT) is challenging. Most clinical trials of systemic therapies for advanced HCC excluded patients with any history of organ transplant. We aimed to assess the outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10268de0d1f45dfaeff136688f4b69a2
https://doi.org/10.1007/s12325-021-01800-z
https://doi.org/10.1007/s12325-021-01800-z
Autor:
Tracy Cy Shum, Yawen Dong, Thomas W. Leung, Wong Hoi She, Bryan Cho Wing Li, Vikki Tang, Cynthia S Y Yeung, Thomas Yau, Jeffrey Sum Lung Wong, Gerry Gin-Wai Kwok, Josephine Tsang, Ka Wing Ma, Ada Law, Anna Tai, Joanne Chiu, Tan To Cheung, Roland Leung
Publikováno v:
Cancers
Volume 13
Issue 9
Cancers, Vol 13, Iss 2002, p 2002 (2021)
Volume 13
Issue 9
Cancers, Vol 13, Iss 2002, p 2002 (2021)
Simple Summary The vascular endothelial growth factor and c-MET pathways are strongly implicated in hepatocellular carcinoma (HCC). Cabozantinib inhibits both pathways and has been approved in sorafenib-exposed advanced HCC (aHCC). We aimed to evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ca9ffb8b43e9325dbc8cffb9d3bf489
http://europepmc.org/articles/PMC8122581
http://europepmc.org/articles/PMC8122581
Autor:
Yawen Dong, Tan To Cheung, Ada Law, Ka Wing Ma, Vikki Tang, Tracy Cy Shum, Roland Leung, Gin Wai Kwok, W.H. She, Thomas W.T. Leung, Anna Tai, Jeffrey Sum Lung Wong, Cynthia S Y Yeung, Joanne Wing Yan Chiu, Thomas Yau, Bryan Li, Wing Yan Josephine Tsang
Publikováno v:
Journal of Clinical Oncology. 39:e16179-e16179
e16179 Background: Cabozantinib is licensed for use as second- or third-line treatment for sorafenib-exposed advanced hepatocellular carcinoma (aHCC) based on the phase III CELESTIAL trial. However, its use in the post-immune checkpoint inhibitors (I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45d441696a4cb28a6be088075f6f37a9
https://doi.org/10.1200/jco.2021.39.15_suppl.e16179
https://doi.org/10.1200/jco.2021.39.15_suppl.e16179
Autor:
Jess L.C. Chan, Tan To Cheung, Gin Wai Kwok, Jeffrey Sum Lung Wong, Wai Meng David Tai, Joycelyn Jie Xin Lee, Su Pin Choo, Joanne Wing Yan Chiu, Thomas Yau, Bryan Li, Vikki Tang, Roland Leung, Wing Yan Josephine Tsang
Publikováno v:
Journal of Clinical Oncology. 39:e16181-e16181
e16181 Background: Immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) are widely adopted in contemporary advanced HCC (aHCC) treatment algorithms. Nevertheless, the optimal strategy for treatment after ICI exposure is unknown.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf4be4e5b35b4d8bb549f32367a5b2c9
https://doi.org/10.1200/jco.2021.39.15_suppl.e16181
https://doi.org/10.1200/jco.2021.39.15_suppl.e16181
Autor:
Wing Yan Josephine Tsang, Gin Wai Kwok, Thomas Yau, Bryan Li, Tan To Cheung, Ka Wing Ma, Jeffrey Sum Lung Wong, W.H. She, Vikki Tang, Roland Leung, Joanne Wing Yan Chiu
Publikováno v:
Journal of Clinical Oncology. 39:e16184-e16184
e16184 Background: Hepatic derangement commonly accompanies advanced HCC (aHCC) and limits the use of systemic therapies. We aimed to evaluate the use of single agent anti-PD-1 nivolumab or pembrolizumab in Child-Pugh (CP) grade B or C patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2cb23ae9f656d733b8ae24d35118edbe
https://doi.org/10.1200/jco.2021.39.15_suppl.e16184
https://doi.org/10.1200/jco.2021.39.15_suppl.e16184
Autor:
Alan C.H. Lee, Joanne W Y Chiu, R. Leung, Vikki Tang, Karen S.L. Lam, Chi Ho Lee, Tan To Cheung, Thomas Yau, Carol H.Y. Fong, Yu Cho Woo, Bryan Cho Wing Li, David T W Lui, Gerry G W Kwok
Publikováno v:
Journal of the Endocrine Society
Introduction: Thyroid immune-related adverse events (irAEs) have been reported to have prognostic significance among cancer patients treated with anti-PD1 and anti-PDL1 monotherapies. There are scanty data in the literature thus far about the clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9546c5f29bbfbf3c3bd9f4d3269564f
http://europepmc.org/articles/PMC8090404
http://europepmc.org/articles/PMC8090404
Autor:
Joanne Chiu, Thomas Yau, Chung Mau Lo, Bryan Cho Wing Li, Jeffrey Sum Lung Wong, Ka Wing Ma, Josephine Tsang, Gerry Gin Wai Kwok, Tan To Cheung, Vikki Tang, Roland Leung, Wong Hoi She
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
BackgroundProgrammed cell death protein 1 (PD-1) pathway blockade with immune checkpoint inhibitors (ICIs) is a standard therapy in advanced hepatocellular carcinoma (HCC) nowadays. No strategies to overcome ICI resistance have been described. We aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::627bcbe652eea3c3d5d4c78657177083
https://doi.org/10.1136/jitc-2020-001945
https://doi.org/10.1136/jitc-2020-001945
Autor:
Jeffrey Sum Lung Wong, Wing Yan Josephine Tsang, Gin Wai Kwok, Ka Wing Ma, Roland Leung, Tan To Cheung, Joanne Wing Yan Chiu, W.H. She, Vikki Tang, Thomas Yau, Bryan Li
Publikováno v:
Journal of Clinical Oncology. 39:330-330
330 Background: Programmed cell death protein 1 (PD-1) pathway blockade with immune checkpoint inhibitors (ICI) is a standard therapy in advanced hepatocellular carcinoma (HCC) nowadays. No strategies to overcome ICI resistance have been described. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8cd363cdb8b591362ebea83803387da0
https://doi.org/10.1200/jco.2021.39.3_suppl.330
https://doi.org/10.1200/jco.2021.39.3_suppl.330